Growth financing Pharmaloz recently secured a 3M financing infusion in late 2025, signaling available capital for expansion, capacity upgrades, or new packaging lines that sales teams can target with supply agreements or co-investment opportunities.

Capacity expansion Past investments to double pouch packaging capacity by 2023 indicate a track record of scaling manufacturing capabilities; positioning for repeatable, higher-volume lozenge packaging partnerships with retailers, contract manufacturers, or private label programs.

Private label potential As a family-owned manufacturer focused on lozenges with packaging capabilities, Pharmaloz may be a fit for brands seeking turnkey private label lozenges, co-manufacturing, or white-label health supplements to accelerate go-to-market timelines.

SMB targeting With a lean team size and revenue in the low single-digit millions, Pharmaloz presents an opportunity for mid-market suppliers of packaging equipment, testing services, and regional distribution partnerships that cater to small to mid-sized pharma manufacturers.

Digital & compliance readiness The visible tech stack includes cloud and web infrastructure usage; engaging Pharmaloz on digital commerce enablement, regulatory compliance support, quality management, and serialization solutions could streamline their operations and open cross-sell avenues.